This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters

Correction for “Desvenlafaxine and Weight Change in Major Depressive Disorder”

Karen A. Tourian, MD; Claire Leurent, PhD; Jay Graepel, PhD; and Philip T. Ninan, MD

Published: November 7, 2011

Correction

In the article “Desvenlafaxine and Weight Change in Major Depressive Disorder” by Karen A. Tourian, MD, and colleagues published in Volume 12, Issue 1 (Prim Care Companion J Clin Psychiatry 2010;12[1]:e1-e8), the symbols for the P values in Figure 3B were transposed. The online article at PrimaryCareCompanion.com has been corrected. The staff regret the error.

Volume: 13

Quick Links: Side Effects-Medication , Weight

$40.00

Buy this Article as a PDF

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...